Table 1.
Participant characteristics.
Table 2.
Biomarkers of hyperglycemia by group.
Fig 1.
Scatterplots of glycated hemoglobin A1c (HbA1c) versus fasting glucose (FG), fructosamine versus FG, and HbA1c versus fructosamine for control and SCT groups.
The best-fit model (solid line) is shown for each plot along with the coefficient of determination (R2), the Pearson correlation coefficient, and the p-value of the correlation.
Fig 2.
Bland-Altman plots showing the agreement between glycated hemoglobin A1c (HbA1c) and fasting glucose (FG) (plots A and B), fructosamine and FG (plots C and D), and HbA1c and fructosamine (plots E and F) for the control (plots A, C, and E) and sickle-cell trait groups (plots B, D, F).
Each plot represents the mean of the two methods (x-axis) against their differences. The mean difference between the two methods (bias) is shown, as are the Upper (UL) and Lower limits (LL) of agreement. %CP HbA1c = percent of the clinical cut-point of HbA1c. %CP FG = percent of the clinical cut-point of fasting glucose. %CP Fructosamine = percent of the clinical cut-point of fructosamine.
Table 3.
Number of subjects classified as over the clinical cut-point for each biomarker of hyperglycemia.
Table 4.
Average fasting glucose, HbA1c, and fructosamine in subjects classified as having prediabetes and subjects classified as over the clinical cut point in the control and SCT groups.